- Home
- UTF vs NAMS Comparison
UTF vs NAMS Comparison
Compare UTF & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTF
- NAMS
- Stock Information
- Founded
- UTF 2004
- NAMS 2019
- Country
- UTF United States
- NAMS Netherlands
- Employees
- UTF N/A
- NAMS N/A
- Industry
- UTF Finance Companies
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- UTF Finance
- NAMS Health Care
- Exchange
- UTF Nasdaq
- NAMS Nasdaq
- Market Cap
- UTF 2.5B
- NAMS 2.7B
- IPO Year
- UTF N/A
- NAMS N/A
- Fundamental
- Price
- UTF $24.65
- NAMS $18.57
- Analyst Decision
- UTF
- NAMS Strong Buy
- Analyst Count
- UTF 0
- NAMS 7
- Target Price
- UTF N/A
- NAMS $41.33
- AVG Volume (30 Days)
- UTF 266.0K
- NAMS 618.3K
- Earning Date
- UTF 01-01-0001
- NAMS 03-04-2025
- Dividend Yield
- UTF 8.21%
- NAMS N/A
- EPS Growth
- UTF N/A
- NAMS N/A
- EPS
- UTF N/A
- NAMS N/A
- Revenue
- UTF N/A
- NAMS $33,594,000.00
- Revenue This Year
- UTF N/A
- NAMS $131.53
- Revenue Next Year
- UTF N/A
- NAMS N/A
- P/E Ratio
- UTF N/A
- NAMS N/A
- Revenue Growth
- UTF N/A
- NAMS 78.77
- 52 Week Low
- UTF $18.15
- NAMS $15.19
- 52 Week High
- UTF $24.49
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- UTF 58.81
- NAMS 29.65
- Support Level
- UTF $24.36
- NAMS $18.88
- Resistance Level
- UTF $24.60
- NAMS $20.46
- Average True Range (ATR)
- UTF 0.26
- NAMS 1.11
- MACD
- UTF 0.02
- NAMS -0.09
- Stochastic Oscillator
- UTF 94.20
- NAMS 5.84
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.